ClinicalTrials.gg
Active, not recruitingNCT05139602Updated Feb 13, 2026

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

A Phase 2 interventional study of Lutikizumab and Placebo in Hidradenitis Suppurativa, sponsored by AbbVie. Active, not recruiting at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.

Enrollment
7th of 11
210 · median 243
Started
2021
the only one that year
Phase 2
4 of 18
1 open now
Registered
14th of 18
by date

Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 2, and was the 14th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hidradenitis Suppurativa by AbbVie, or all of them as a file.
02

Study summary

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for patients who fail to achieve adequate benefit with anti-TNF therapy. This study will compare lutikizumab (ABT-981) versus placebo for the treatment of adult participants with moderate to severe HS who have failed anti-TNF therapy.

Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS. In the Main Study, participants will be put in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that participants will be assigned to placebo. Around 160 adult participants with moderate to severe HS who have failed anti-TNF therapy will be enrolled in the study at approximately 50 sites worldwide. In the Sub-study, participants will be put in 1 of 2 groups, called treatment arms. Both arms will receive treatment at different dosing intervals. Around 40 adult participants with moderate to severe HS who are naïve to biologic therapy will be enrolled in the study at approximately 20 sites.

In the Main Study, participants will receive subcutaneous injections of lutikizumab (ABT-981) or placebo every week for 16 weeks. In the Sub-study, participants will receive subcutaneous injections of lutikizumab (ABT-981) every week for the first 15 weeks, then either every week or every other week for 36 weeks. There will be an optional Long Term Extension (LTE) for participants who completed Week 52 of the Sub-study and, as confirmed by the investigator, have shown a therapeutic benefit to study drug. Participants would then received lutikizumab using the same assigned dosing regimen as that from Period 2 of the Sub-study for an additional 104 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • Lutikizumab
  • ABT-981
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline as determined by the investigator.
  • A total abscess and inflammatory nodule (AN) count of >= 5 at Baseline
  • HS lesions must be present in at least 2 distinct anatomic areas.
  • Must have failed anti-TNF treatment for HS.
  • To be eligible for the Sub-study, participants must be naïve to biologic therapy for treatment of HS.

Exclusion criteria

Exclusion Criteria:

- History of active skin disease other than HS that could interfere with the assessment of HS, including skin infections (e.g., bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline visit.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Main Study: Lutikizumab Dose A

    Lutikizumab Dose A every week

    Biological: Lutikizumab

  • Experimental
    Main Study: Lutikizumab Dose B

    Lutikizumab Dose B every other week

    Biological: Lutikizumab

  • Experimental
    Main Study: Lutikizumab Dose C

    Lutikizumab Dose C every other week

    Biological: Lutikizumab

  • Placebo comparator
    Main Study: Placebo

    Placebo every week

    Drug: Placebo

  • Experimental
    Sub-study: Group 1

    Period 1: Lutikizumab Dose A every week. Period 2: Lutikizumab Dose A every week.

    Biological: Lutikizumab

  • Experimental
    Sub-study: Group 2

    Period 1: Lutikizumab Dose A every week. Period 2: Lutikizumab Dose A every other week.

    Biological: Lutikizumab

Interventions

  • BiologicalLutikizumab

    Subcutaneous Injection

    Also known as: ABT-981

  • DrugPlacebo

    Subcutaneous Injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Hidradenitis Suppurative Clinical Response (HiSCR)

    HiSCR is defined as at least a 50% reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase in abscess count and no increase in draining fistula-count relative to Baseline.

    Time frame: Week 16

  2. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately Week 68

Secondary outcomes

  1. Percentage of Participants Achieving Numeric Rating Scale (NRS) 30 among Participants with Baseline NRS >=3

    NRS 30 is defined as at least a 30% reduction and at least 1-unit reduction from Baseline in worst skin pain (maximal daily pain), as assessed by the Patient's Global Assessment (PGA) of Skin Pain.

    Time frame: Week 16

07

Study locations

54 sites
08

References and documents

Publications

  • Kimball AB, Sawicki KT, Ackerman L, Lima H, Giamarellos-Bourboulis EJ, Zhan T, Drogaris L, Gu Y, Lee CM, Akbari M, Williams DA, Bechara FG. Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial. JAMA Dermatol. 2026 May 1;162(5):469-477. doi: 10.1001/jamadermatol.2026.0155. PubMed 41848710 ↗

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2027, 72 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's planned 72 months is above that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Dec 1, 2021
StartActual
Dec 28, 2021
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05139602
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Dec 28, 2021
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutikizumab

Start the discussion